Leadership Team

Meet Our Associates

Borys Chabursky

 - Founder and Chairman

Borys Chabursky founded Shift Health to develop convergent solutions that improve human health and wellbeing. With Borys’ oversight, Shift Health has successfully delivered over 500 life sciences assignments for more than 300 clients in North America, Europe and the Middle East.

In addition to his role as Founder and Chairman of Shift Heath, Borys serves as the Chairman of SHI Capital, a boutique investment bank, and President of SHI Ventures, a vehicle through which he has invested as an angel in over 40 companies including 15 life sciences start-ups.

Borys is a member of the advisory boards of GEMMA Biotechnology, Mineara Alamos Inc. and Temperance Capital. He is also a member of the Young Presidents’ Organization (YPO) and a board member of the Maple Leaf Chapter (Greater Toronto Chapter).

Borys is a sought-after speaker and has been named one of Canada’s “Top 40 Under 40”. He has been featured in international television, radio and print media including Canadian Business, CBC, Global TV, The National Post, Site Selection, BioBusiness, Life Science Today, Biotechnology Focus, The China Post, Les Echos, Turkish Daily News, The Peterborough Examiner, The Hamilton Spectator and Business Executive.

Dr. Ryan Wiley

 - President

Dr. Ryan Wiley brings incisive strategy and an unrelenting commitment to results to every Shift Health engagement. Working with global leaders in the contexts of business, healthcare, science and policy, Ryan has a unique ability to envision and unlock the benefits of convergence across the HealthSphere.

With extensive experience in corporate, R&D and innovation strategy, opportunity evaluation, implementation oversight, capacity-building and public-private partnerships, Ryan has successfully worked with multinational companies, governments, academic institutions, not-for-profit organizations and healthcare providers around the world. He has effectively facilitated and managed ground-breaking alliances that have opened new markets and leveraged hundreds of millions of dollars in investment, and he has worked seamlessly with the public and private sectors on system transformation, economic development, health research, global health and commercialization initiatives across North America, Latin America, Europe, Southeast Asia, Sub-Saharan Africa and the Middle East.

Ryan is an Assistant Professor at McMaster University, Chair of Research Canada, Director of CanHealth International, Director of Amref Health Africa, past Director of Women’s College Hospital Foundation, founding Co-chair of neWCHapter at Women’s College Hospital Foundation, past Chair of New Leaders of Sunnybrook Foundation and Advisor to the Ontario Brain Institute. Ryan holds a PhD in immunology from McMaster University and has published in the areas of asthma/allergy, immunology, pharmacology and gene therapy.

Charles Khoury

 - Engagement Leader

Charles Khoury integrates complementary expertise in life sciences research and business strategy to deliver powerful insights that reflect the nuances of health innovation and the realities of effective implementation.

Charles has extensive experience in market assessment, opportunity identification and evaluation, and strategic and business planning for life sciences research and innovation organizations. He has led an expansive portfolio of high-profile projects spanning the spectrum of the HealthSphere: advancing the research strategies of some of Canada’s most prestigious academic institutions; planning national health innovation infrastructure in the Middle East; working with top-5 biopharmaceutical firms headquartered in the US and Europe in strengthening market position; and helping health research organizations in Latin America and Africa secure partners and funding.

Prior to joining Shift Health, Charles established a foundational skillset in life sciences strategy consulting through his work with the Mensa Process, and he developed a nuanced understanding of operations and finance in a planning and performance management role for a multibillion dollar, multinational company. Charles earned his MSc in Medical Genetics and Microbiology from the University of Toronto—conducting basic research in the field of virology—and earned an MBA from the Schulich School of Business at York University—majoring in Strategy and Marketing.

Dr. Anne Mullin

 - Engagement Leader

Dr. Anne Mullin works with leading decision-makers across the HealthSphere to amplify the impact of biomedical discoveries and healthcare innovations on the health and wellbeing of populations in both developed and developing countries.

Anne’s collaborative approach to working with clients and rich academic track record in the study of infectious disease have supported the sustainability and success of numerous international product development consortia, allowed both industry and academic partners to manage risk of high-impact clinical trials, and helped clients from industry, academia and the not-for-profit sector attract capital, establish partnerships and drive innovation. Having led engagements in North America, Europe, Southeast Asia and Africa, Anne’s client base spans the globe.

Prior to joining Shift Health, Anne was a postdoctoral fellow and lecturer in the department of Pathology and Laboratory Medicine at the University of British Columbia. While at UBC, Anne was also a committed leader in the public communication of science within British Columbia and Director of the Society for Canadian Women in Science and Technology. Anne graduated with an MSc from the London School of Hygiene and Tropical medicine, a PhD in virology from The University of Cambridge and an MBA from the Richard Ivey School of Business, where she specialized in healthcare and life sciences strategy.

Dr. Chris Delvecchio

 - Engagement Leader

Dr. Chris Delvecchio is driven by a passion to solve complex challenges and affect positive change across the HealthSphere. Working with leading companies, investor groups and healthcare and academic organizations globally, Chris has led multifaceted initiatives that have produced measurable impact for his clients.

Chris has deep experience in developing original strategies and business plans that help organizations assume or retain a position of leadership, conducting in-depth opportunity evaluations that underpin major investment decisions and building research capacity that aligns programs with patient and market needs. His work has helped public and private organizations across North America, Europe, Asia and the Middle East define their competitive niche, unlock new sources of revenue and advance innovation in order to realize the full health and socioeconomic potential of their work.

In addition to his work with Shift Health, Chris volunteers his time with Life Sciences Ontario’s mentorship program and with new entrepreneurs seeking to translate their ideas into thriving start-ups. Previously, Chris served as a Project Manager for an early-stage drug discovery company developing the world’s first high-throughput live animal screening system to test new drugs. Chris graduated with a PhD in Biochemistry and Biomedical Sciences from McMaster University where he specialized in endocrinology and nuclear hormone receptors. He has presented his research at several international scientific conferences and has published his work in top-tier journals.

 

Associates

Meet Our Leadership Team

Dr. Michael Julius

 - Associate

Dr. Michael Julius is the Vice President, Research, Sunnybrook Health Sciences Centre, where he stewards a $125M annual research enterprise. His work towards understanding the biochemistry of lymphocyte activation, and the cellular and molecular interactions culminating in protective immunity have supported his continuing interest in autoimmune diseases, and ailments that involve dysregulated function of the immune system.

Having published over 200 research papers and reviews in his area of expertise, many of which have achieved citation records, Michael is an internationally recognized immunologist. Academic Press, now Elsevier, engaged Michael as the Editor of the highly cited review periodical, Seminars in Immunology.

Michael has Chaired the Canadian Institutes for Health Research review panel for “Immunology and Transplantation”, and serves as a member of Scientific Advisory Boards for a number of for profit enterprises. He was elected Vice Chair of the Board of Directors of Research Canada in April 2007, and assumed the Chair of Research Canada in May 2008, stepped down in November 2010 and served as Past Chair in 2011 and now serves as Scientific Advisor.

Michael received an Honours B.Sc. degree in genetics from McGill University in Montréal, Quebec, and went on to do his doctoral work at Stanford University in Palo Alto, California culminating in a Ph.D. in genetics and immunology.

John Soloninka

John Soloninka

 - Associate

John Soloninka has over 23 years of experience in medical technology consulting, company formation, growth and management. He has led major projects in health system transformation, biopharma/device development/regulation, health IT, disease management, clinical trials, clinical genomics, and venture capital including for Price Waterhouse and IBM. Prior to joining Baton Pharma, John was President and Chief Executive Officer of The Health Technology Exchange, a life sciences venture fund where he deployed capital into 33 companies over 5 years.

A Professional Engineer and MBA, John was a founder, senior executive and leader in start-up companies in oncology, radiology and internet-based EMR and clinical trials which were variously sold to Varian Medical Systems, Merge Technologies and Assistmed, all of the U.S. He served as Life Sciences Industry Advisor at Department of Foreign Affairs, Trade & Development (DFATD). John served on the Board of Directors at Baycrest.

John also served as a Director or Advisory Board Member at CImTeC (the Centre for Imaging Technology and Commercialization), the Ontario Brain Institute, and EXCITE (Excellence in Clinical Innovation and Technology Evaluation). John graduated from Queen’s University in Engineering Physics and holds a MBA, with Distinction, from the University of London in England.

Dr. Yazid Ohaly

 - Associate

Dr. Yazid Ohaly is a prominent member of the healthcare and life sciences sectors in Saudi Arabia. A former member of the Shura Council and former Director General of Hospitals Administration for the Saudi Ministry of Health, Yazid brings in-depth knowledge of public policy in Saudi Arabia and has worked closely with various Saudi universities, research centres and hospitals. He is the founder of Ohaly Healthcare Consulting, a strategy firm that works at the nexus of the public and private sectors in the Kingdom of Saudi Arabia, working for various national and international stakeholders from government, academia, industry and hospitals on healthcare-related matters.

Yazid is a Swedish board-certified respiratory medicine specialist. He has been a board member of several national and international committees and has presented his work at various international conferences. Notably, Yazid served as a board member of Joint Commission Resources for three years, where he worked toward establishing an internationally accepted hospital accreditation system to improve patient safety globally. He is currently a member of the Board of the National Medical Care Company and former Chairman of the Board of SABB Takaful, a licensed insurance company that enjoyed an expansion in operations during his leadership. SABB Takaful was named Best Takaful Provider for 2009 in Euromoney Global Awards and also Best Takaful Product and Best Takaful Marketing at the 2nd International Takaful Awards.

Dr. Edward William Hillhouse BSc, MB. BS., PhD, FRCP, is Chief of Scientific, Faculty and Academic Affairs and Chief Policy Advisor on Academic Health Systems at Hamad Medical Corporation (HMC) in Doha; Professor of Medicine at Weill Cornell Medical College in New York; and, Emeritus Professor of Medicine at the University of Leeds.

Dr. Edward Hillhouse

 - Associate

Dr. Edward William Hillhouse BSc, MB. BS., PhD, FRCP, is former Chief of Scientific, Faculty and Academic Affairs and Chief Policy Advisor on Academic Health Systems at Hamad Medical Corporation (HMC) in Doha; Professor of Medicine at Weill Cornell Medical College in New York; and, Emeritus Professor of Medicine at the University of Leeds.

Since his appointment in 2011, Ed has worked with Dr. Hanan Al-Kuwari and other senior leaders to galvanise HMC with the vision of a national academic health system that brings together Qatar’s academic institutions and healthcare providers into a single unified healthcare partnership. He is a board member of HMC, which provides 90% of the healthcare in Qatar through a network of eight general and specialist hospitals, with three new hospitals opening in 2016. HMC was recently accredited as an Academic Medical Center by the Joint Commission International.

Ed is a consultant endocrinologist with special expertise in metabolic bone disease and pituitary disorders. He qualified from St Thomas’ Hospital in London and undertook postgraduate training in Oxford, London, Boston and Melbourne. An internationally recognised clinical scientist, his most influential work has been in defining the molecular mechanisms underlying the role of stress in health and disease. He has extensive experience in translational clinical research and clinical trials.

Ed previously held the post Professor of Medicine at the University of Leeds where he served as Dean of the School of Medicine, Faculty Dean of Medicine and Health and Dean for International Development. Under his leadership, the Faculty of Medicine at Leeds was transformed with a new vision and strategy that led to the creation of several major interdisciplinary research institutes.

Ed also served as a non-executive director on the board of the largest teaching hospital in Europe. He was also Professor of Medicine at the University of Warwick where he established the Medical Research Institute and helped lead the successful bid to establish a graduate school of medicine at Warwick. He is a founding member and Consulting Director of the International Association of Academic Health Centers (AAHCI) and is passionate about the role of academic health centers as vehicles for innovation and health improvement.

Roland Turck, Associate at Shift Health

Dr. Roland Turck

 - Associate

Dr. Roland Turck is a biopharmaceutical industry expert, Managing Partner of TurckBio and Associate of Shift Health. Dr. Turck has been involved in many significant projects, including improving the P&L of a division of a large Specialty Medicine company, developing regional strategies, preparing product launches, advising on clinical development strategies, as well as business development and partnering activities for small and large companies.

Dr. Turck was previously President of Bayer’s Global Specialty Medicine Business, which included the Oncology, Neurology, Orphan Drug, Ophthalmology and Diagnostic Imaging businesses. During his tenure, he orchestrated the launch of 4 major global brands, including Xofigo and Eylea, established Bayer as a player in Ophthalmology, re-organized the Diagnostic Imaging business, and aggressively expanded the Hemophilia and Neurology businesses.

Before joining Bayer, Dr. Turck was President of Bayer Schering Pharma’s Latin American business, with full P&L responsibility for all therapeutic areas and sales of US$1.5B. In earlier roles, he was CEO of subsidiaries in Canada and New Zealand and head of Marketing and R&D for a business unit in Germany.